ViCentra Releases New Kaleido Automated Insulin Delivery Patch Pump System

ViCentra has commercially launched its new smartphone-controlled hybrid closed loop system, with first commercial deliveries in Germany and the Netherlands planned for later this summer.

The new system brings together Kaleido—billed as the smallest, lightest, and most precise insulin patch pump in its class—with Diabeloop’s self-learning DBLG2 algorithm and Dexcom G7 Continuous Glucose Monitoring (CGM) system to deliver a more streamlined hybrid closed loop experience. Designed to fit more naturally into daily life, Kaleido is discreet, intuitive, and personalized, giving diabetics greater flexibility and choice in their therapy management.

The system enables hybrid closed loop therapy to be controlled directly from a smartphone rather than a separate dedicated handset. Dexcom G7 further enhances the experience with its smaller, all-in-one sensor and transmitter, making the overall system more streamlined and convenient to use, according to the company.

Following a pilot launch in the Netherlands, ViCentra is currently moving into commercial execution in Germany and the Netherlands. With the commercial version of the system now ready for market, ViCentra will formally unveil the new system at the 60th DDG Diabetes Congress in Berlin, the annual congress of the German Diabetes Association (Deutsche Diabetes Gesellschaft), ahead of first deliveries later this summer.

“This is an important milestone for ViCentra and an exciting step forward for people with diabetes in Germany and the Netherlands,” ViCentra CEO Tom Arnold stated. “With Kaleido, DBLG2 and Dexcom G7, we are making automated insulin delivery simpler, more flexible, and easier to live with. It brings together smartphone control, the latest CGM technology, and Kaleido’s design in a way that fits more naturally into everyday life.”

Begin with Kaleido and Diabeloop’s DBLG1 algorithm today for the fastest transition to DBLG2 and Dexcom G7 integration. This allows healthcare professionals to start therapy for people with diabetes now, before they are smoothly transitioned to the new system upon its availability.

Over the past year, ViCentra has expanded its commercial presence in Germany and the Netherlands, strengthened its operational readiness, and continued building the capabilities needed to support future growth in Europe and the United States The introduction of Kaleido with Diabeloop’s DBLG2 algorithm and Dexcom G7 marks the next step in ViCentra’s strategy to scale a differentiated insulin delivery platform and expand access to automated insulin delivery. ViCentra will provide further updates on availability and transition pathways as the launch approaches.

ViCentra develops and manufactures the Kaleido insulin patch pump, a flexible, discreet alternative to traditional insulin pumps. Headquartered in Utrecht, the Netherlands, ViCentra is expanding across Europe and preparing for U.S. market entry. Its investors include Innovation Industries, Partners in Equity, Invest-NL, EQT Life Sciences, ROM Utrecht Region, Venturing Tech, Health Innovations and INKEF. 

Kaleido is attempting to redefine wearable insulin delivery through the first insulin patch pump designed with the form, function, and simplicity of a lifestyle product. Compact, featherlight, and discreet, Kaleido is designed with a focus on personal technology rather than a traditional medical device. It is made from premium materials and features customizable aluminum shells in 10 color options. It offers users flexibility in the ways in which and where they wear their pump, allowing people with diabetes to manage their therapy in a way that fits seamlessly into their daily lives. It is reportedly the smallest, lightest, most precise insulin patch pump in its class—delivering advanced, automated insulin therapy through seamless integration with Diabeloop’s clinically validated hybrid closed loop algorithms, DBLG1 and DBLG2.